Jack Cuzick

Jack Cuzick, PhD, FRS is the John Snow Professor of Epidemiology and founding Director of the Centre for Cancer Prevention at Queen Mary University of London. He is the world's foremost authority on breast cancer chemoprevention, having led both IBIS-I and IBIS-II, the two landmark International Breast Cancer Intervention Study trials that established tamoxifen and anastrozole, respectively, as effective preventive agents in high-risk women. The IBIS-I trial, initiated in 1992 and reported in The Lancet in 2002 and with long-term follow-up in 2015, demonstrated that five years of tamoxifen reduced breast cancer incidence by approximately 29% in high-risk premenopausal and postmenopausal women, with the benefit persisting for at least 20 years. The subsequent IBIS-II trial, reported in The Lancet in 2014, demonstrated that anastrozole reduced breast cancer incidence by 53% in postmenopausal high-risk women over five years with continued benefit beyond treatment, establishing an aromatase inhibitor as the preferred preventive agent in postmenopausal women. Professor Cuzick also developed the Tyrer-Cuzick model, one of the most widely used breast cancer risk prediction tools globally, integrating family history, hormonal factors, and lifestyle variables to identify women who would benefit most from preventive interventions. He has authored over 500 peer-reviewed publications, served on advisory boards for NICE and the FDA, and his work has directly translated into clinical guidelines across the UK, USA, and Europe that now recommend risk-stratified chemoprevention as standard of care for eligible high-risk women.